Cloud-based Software for the Global Life Sciences Industry

Veeva is a leading global provider of industry-specific, cloud-based software solutions for the life sciences industry. Our solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance.

Latest News

December 13, 2021 Veeva Acquires Veracity Logic for Randomization and Trial Supply Management (RTSM)
Veeva RTSM adds to Veeva's end-to-end clinical suite   Veeva Systems (NYSE: VEEV) today announced it has acquired Veracity Logic, a provider of cloud software for randomization and trial supply management (RTSM). The Veracity Logic team will join Veeva to deliver industry-leading software and services, helping companies simplify complex processes and expedite clinical trials. The solution, offered as Veeva RTSM , delivers fast setup timelines and a configurable feature set to meet a broad array of randomization and supply needs. It has supported over 175 trials with sites in 60 countries, covering a range of trial designs and complexities across all therapeutic areas in pharma/biotech, medical device, and diagnostics. "We are pleased to have the Veracity Logic team join Veeva and look forward to bringing RTSM excellence to our customers," said Jim Reilly, vice president, Vault R&D and Quality at Veeva Systems. "This expands Veeva's clinical offering with flexible and...
December 1, 2021 Veeva Announces Fiscal 2022 Third Quarter Results
Total Revenues of $476.1M, up 26% Year Over Year; Subscription Services Revenues of $380.7M, up 26% Year Over Year Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its third quarter ended October 31, 2021. "Innovation and consistent execution have us tracking ahead of our 2025 targets and set us up for significant growth beyond," said CEO Peter Gassner. "As the strategic partner to the life sciences industry in its move to new digital and specialty models, we are proud our work will help patients get the therapies they need faster and easier." Fiscal 2022 Third Quarter Results: Revenues : Total revenues for the third quarter were $476.1 million, up from $377.5 million one year ago, an increase of 26% year over year. Subscription services revenues for the third quarter were $380.7 million, up from $302.9 million one year ago, an increase of 26% year over year. Operating Income...

Investor Contact

Ato Garrett

Email Alerts

Email *
Mailing Lists *

Enter the code shown above.